CG 200745

Drug Profile

CG 200745

Alternative Names: CG 200745 phosphoric acid; CG 200745 PPA; CG200745

Latest Information Update: 27 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CrystalGenomics
  • Class Antineoplastics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Myelodysplastic syndromes; Pancreatic cancer

Most Recent Events

  • 23 Apr 2018 CBT Pharmaceuticals and CrystalGenomics agree to co-develop and co-promote Genolimzumab and CG 200745 worldwide for Solid tumours (Combination therapy)
  • 23 Apr 2018 CBT Pharmaceuticals and CrystalGenomics plan a phase Ib/II trial for Solid tumours (Combination therapy) by the end of 2018
  • 01 Jun 2016 Phase-I/II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top